KRAS and neoplasm: Furthermore, KRAS mutations were shown to upregulate GM-CSF expression in the TME, enhancing the infiltration of MDSCs which are known to be potent suppressors of effector T cell responses and therefore contribute to the evasion of anti-tumor immunity (187–190).